We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Lateral-Flow Assay Rapidly Detects Plague Bacteria

By LabMedica International staff writers
Posted on 28 Aug 2018
Print article
Image: Specificity assay of Yersinia F1-strips. Six Yersinia strains (105 CFU/mL each) were applied on Yersinia-F1-strips. Strip 1: Y. pestis yreka; 2: Y. mollaretii; 3: Y. frederiksenii; 4: Y. pseudotuberculosis; 5: Y. enterocolitica; 6: Y. intermedia; 7: PCB buffer (Photo courtesy of National Defense Medical Center).
Image: Specificity assay of Yersinia F1-strips. Six Yersinia strains (105 CFU/mL each) were applied on Yersinia-F1-strips. Strip 1: Y. pestis yreka; 2: Y. mollaretii; 3: Y. frederiksenii; 4: Y. pseudotuberculosis; 5: Y. enterocolitica; 6: Y. intermedia; 7: PCB buffer (Photo courtesy of National Defense Medical Center).
Plague caused by Yersinia pestis is a known flea-borne disease that can trigger large epizootics among the rodent population. Humans that live in environments close to these rodents can contract the bubonic plague either through direct contact with infected animals or through transmission by infective flea bites.

Over the last decade, thousands of cases of plague have been reported annually, indicating that the plague has not been eliminated. This is especially true in places where public health and living conditions are poor. Several well-established assays have been applied to detect Y. pestis/F1 protein, such as the indirect hemagglutination assay (IHA), which is the current gold standard for Y. pestis detection.

Scientists at the National Defense Medical Center (Taipei, Taiwan) developed a rapid, cheap, sensitive, and specific technique, the lateral flow assay (LFA -F1 strips), to detect this pathogen, by using paired monoclonal antibodies (MAbs) against Y. pestis capsule like fraction 1 (F1) protein. Compared with the polyclonal antibody (PAb) based F1 strips, the MAb-based F1 strips have a remarkable increased detection limitation (10 to 100 fold). Furthermore, besides the limitation and specificity evaluation, the application of this F1 strip on simulated clinical samples indicate the LFA can be a good candidate to detect plague.

Recombinant F1 antigen was expressed and purified from a series of studies. The various anti-F1 monoclonal antibodies (MAbs) generated from hybridoma cells were screened with the enzyme-linked immunosorbent assay (ELISA) technique. To evaluate the feasibility of this Y. pestis F1 test strip, the F1 protein/Y. pestis was spiked into simulated clinical samples such as human serum, mouse bronchoalveolar lavage fluids, and mouse blood to mimic natural infection status. Additionally, this technique was applied to detect the Y. pestis in the environment-captured rats, to evaluate the practical usefulness of the strips.

The scientists reported that by using this MAb-based-LFA technique, 4 ng/mL of recombinant F1-protein and 103 CFU/mL of Y. pestis could be detected in less than 10 minutes, which is at least 10-folds than that of the polyclonal antibody (PAb) format. On the other hand, although various Yersinia strains were applied to the strips, only Y. pestis strain showed a positive result; all other Yersinia species did not produce a positive signal, indicating the high efficiency and specificity of the MAb-based F1-strips.

The authors concluded that the MAb-format-LFA will be valuable as a diagnostic tool for the detection of Y. pestis. This report shows that the F1 strip is sufficient to support not only the detection of plague in simulated clinical samples, but also it may be a good candidate to meet the epidemiological surveillance during an outbreak of the biological warfare. The study was published on August 14, 2018, in the journal BMC Infectious Diseases.

Related Links:
National Defense Medical Center

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The breakthrough could result in a higher success rate using a simple oral swab test before IVF (Photo courtesy of Shutterstock)

POC Oral Swab Test to Increase Chances of Pregnancy in IVF

Approximately 15% of couples of reproductive age experience involuntary childlessness. A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.